CRISPR/Cas9 is a gene editing tool that has revolutionized biomedical research and led to the first FDA-approved CRISPR-based gene therapy.

In Usher syndrome, genetic mutations cause both hearing and vision loss. Cell biologist Professor Uwe Wolfrum from Mainz University is researching the molecular background of this rare genetic ...

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant ...

The traditional randomised controlled trial (RCT) model has been used for decades in drug development. Although it is ...

Using state-of-the-art technology, researchers have identified several specific steps needed for CRISPR to become active and perform its gene editing function. These preclinical findings could lead to ...

Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology ...

All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and ...

CAGR offers a clear view of long-term investment trends by balancing fluctuations for a steady growth rate. BCC Research ...

"Discover High-Growth Opportunities Across Leading Sectors, With BCC Research Highlighting Industries Primed for Up to 20% Annual Returns" BOSTON, Oct. 30, 2024 /PRNewswire/ -- CAGR offers ...

RCCS San Raffaele Scientific Institute in Milan researchers have discovered that hematopoietic stem cells (HSCs) adapt their lineage commitment during gene therapy based on the underlying genetic ...

In this GEN webinar, our speakers will present important considerations for quality control testing for biosafety and product ...

Cell and gene therapy companies are the beneficiaries of positive changes along the regulatory path that the U.S. FDA is ...